Anastrozole

—

evidence score

hormonal

Prescription Only

ArimidexAIaromatase inhibitor+1 more

Anastrozole is a third-generation non-steroidal aromatase inhibitor (AI) FDA-approved for hormone receptor-positive breast cancer. In male performance medicine and TRT, it is used to control estradiol elevation from testosterone aromatization. Excessive estrogen during TRT or anabolic steroid use causes water retention, gynecomastia, mood instability, and sexual dysfunction. However, estrogen is essential for men too — bone density, libido, cardiovascular health, and joint function all require adequate estrogen. Anastrozole dosing requires careful titration to labs; over-suppression of estrogen ("crashing estrogen") is common and causes significant symptoms.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Physician Notes

Use sparingly. E2 management is nuanced. Some estradiol is protective for cardiovascular health, bone density, and libido. Manage symptoms, not numbers. Crashing E2 causes joint pain, low libido, and cognitive fog.

FDA Status:FDA-approved for breast cancer. Used off-label in TRT management.

Monitoring

Estradiol (sensitive) q3mo
Lipid panel (AIs can worsen lipids)
Bone density if prolonged use

Contraindications

Osteoporosis
Already low estradiol

Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical

0.5 mg

0.25 mgRange1 mg

Frequencyevery other day to twice weekly

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~50 hours

OnsetEstradiol reduction within 24-48 hours; clinical symptom relief within 1-2 weeks

DurationOngoing aromatase inhibition during use; estrogen recovery 2-3 weeks after stopping

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Anastrozole is currently categorized as a hormonal compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Reversible competitive inhibitor of aromatase (CYP19A1); blocks conversion of testosterone → estradiol; reduces circulating estrogen by 70-80% in men

Practical Context

Strongest current signals

No indexed study summaries yet.